Evidence map›Paper›PMID 35997457›Full record

ArticleJournal of functional biomaterials2022

Application of Injectable, Crosslinked, Fibrin-Containing Hyaluronic Acid Scaffolds for In Vivo Remodeling.

Adél Hinsenkamp, Ágnes Fülöp, László Hricisák, Éva Pál, Kiara Kun, Aliz Majer, Viktória Varga, Zsombor Lacza, István Hornyák

Open access · goldAbstract read
In one paragraph

Article in Journal of functional biomaterials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Editorial: Biomaterial applications in soft tissue engineering and replacement.Frontiers in bioengineering and biotechnology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Adél HinsenkampInstitute of Translational Medicine, Semmelweis University, H-1094 Budapest, Hungary.
Ágnes FülöpInstitute of Translational Medicine, Semmelweis University, H-1094 Budapest, Hungary.
László HricisákInstitute of Translational Medicine, Semmelweis University, H-1094 Budapest, Hungary.
Éva PálInstitute of Translational Medicine, Semmelweis University, H-1094 Budapest, Hungary.ORCID 0000-0003-1793-1912
Kiara KunInstitute of Translational Medicine, Semmelweis University, H-1094 Budapest, Hungary.
Aliz MajerInstitute of Translational Medicine, Semmelweis University, H-1094 Budapest, Hungary.
Viktória VargaInstitute of Translational Medicine, Semmelweis University, H-1094 Budapest, Hungary.
Zsombor LaczaOrthosera Medical Zrt., H-1121 Budapest, Hungary.
István HornyákInstitute of Translational Medicine, Semmelweis University, H-1094 Budapest, Hungary.ORCID 0000-0002-7183-8973
Semmelweis University · HUHungarian University of Sports Science · HU

Funding

Hungarian National Research, Development and Innovation Office 2020-1.1.6-JÖVŐ-2021-00010Hungarian National Research, Development and Innovation Office TKP2021-EGA-21
6 · The paper itself

Abstract

The present research aimed to characterize soft tissue implants that were prepared with the use of crosslinked hyaluronic acid (HA) using two different crosslinkers and multiple reagent concentrations, alone or in combination with fibrin. The effect of the implants was evaluated in an in vivo mouse model, after 4 weeks in one group and after 12 weeks in the other. The explants were compared using analytical methods, evaluating microscopic images, and a histology analysis. The kinetics of the degradation and remodeling of explants were found to be greatly dependent on the concentration and type of crosslinker; generally, divinyl sulfone (DVS) resists degradation more effectively compared to butanediol diglycidyl ether (BDDE). The presence of fibrin enhances the formation of blood vessels, and the infiltration of cells and extracellular matrix. In summary, if the aim is to create a soft tissue implant with easier degradation of the HA content, then the use of 2-5% BDDE is found to be optimal. For a longer degradation time, 5% DVS is the more suitable crosslinker. The use of fibrin was found to support the biological process of remodeling, while keeping the advances of HA in void filling, enabling the parallel degradation and remodeling processes.

Indexed as

biocompatiblecrosslinked hyaluronic acidcryoprecipitateinjectablein vivo remodelingsoft tissue implantvascularization

Identifiers

PMID35997457
PMCPMC9396986
OpenAlexW4291465616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.